AAAAAA
Results:
1-12
|
Results: 12
Authors:
Hershberger, PA
Yu, WD
Modzelewski, RA
Rueger, RM
Johnson, CS
Trump, DL
Citation: Pa. Hershberger et al., Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis, CLIN CANC R, 7(4), 2001, pp. 1043-1051
Authors:
Modugno, F
Weissfeld, JL
Trump, DL
Zmuda, JM
Shea, P
Cauley, JA
Ferrell, RE
Citation: F. Modugno et al., Allelic variants of aromatase and the androgen and estrogen receptors: Toward a multigenic model of prostate cancer risk, CLIN CANC R, 7(10), 2001, pp. 3092-3096
Authors:
Obasaju, C
Manola, J
Hudes, GR
Khandekar, JD
Citrin, DL
Carbone, P
Trump, DL
Citation: C. Obasaju et al., Phase II evaluation of menogaril in advanced prostate cancer - Eastern Cooperative Oncology Group EST P-A885, AM J CL ONC, 24(2), 2001, pp. 150-154
Authors:
Trump, DL
Waldstreicher, JA
Kolvenbag, G
Wissel, PS
Neubauer, BL
Citation: Dl. Trump et al., Androgen antagonists: Potential role in prostate cancer prevention, UROLOGY, 57(4A), 2001, pp. 64-67
Authors:
Winters, SJ
Brufsky, A
Weissfeld, J
Trump, DL
Dyky, MA
Hadeed, V
Citation: Sj. Winters et al., Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men, METABOLISM, 50(10), 2001, pp. 1242-1247
Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo
Authors:
Konety, BR
Lavelle, JP
Pirtskalaishvili, G
Dhir, R
Meyers, SA
Nguyen, TST
Hershberger, P
Shurin, MR
Johnson, CS
Trump, DL
Zeidel, ML
Getzenberg, RH
Citation: Br. Konety et al., Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo, J UROL, 165(1), 2001, pp. 253-258
Authors:
McGuire, TF
Trump, DL
Johnson, CS
Citation: Tf. Mcguire et al., Vitamin D-3-induced apoptosis of murine squamous cell carcinoma cells - Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1, J BIOL CHEM, 276(28), 2001, pp. 26365-26373
Authors:
Zeng, Q
Smith, DC
Suscovich, TJ
Gooding, WE
Trump, DL
Grandis, JR
Citation: Q. Zeng et al., Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole, CLIN CANC R, 6(6), 2000, pp. 2245-2251
Authors:
Smith, DC
Johnson, CS
Freeman, CC
Muindi, J
Wilson, JW
Trump, DL
Citation: Dc. Smith et al., A phase I trial of calcitriol (1,25-dihydroxycholecalciferol) in patients with advanced malignancy, CLIN CANC R, 5(6), 1999, pp. 1339-1345
Authors:
Bubley, GJ
Carducci, M
Dahut, W
Dawson, N
Daliani, D
Eisenberger, M
Figg, WD
Freidlin, B
Halabi, S
Hudes, G
Hussain, M
Kaplan, R
Myers, C
Oh, W
Petrylak, DP
Reed, E
Roth, B
Sartor, O
Scher, H
Simons, J
Sinibaldi, V
Small, EJ
Smith, MR
Trump, DL
Vollmer, R
Wilding, G
Citation: Gj. Bubley et al., Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group, J CL ONCOL, 17(11), 1999, pp. 3461-3467
Authors:
Woolley, PV
Freiha, FS
Smith, DC
Carlson, L
Hofacker, J
Quinn, N
Grove, W
Trump, DL
Citation: Pv. Woolley et al., A phase II trial of CI-958 in patients with hormone-refractory prostate cancer, CANC CHEMOT, 44(6), 1999, pp. 511-517
Authors:
Hershberger, PA
Modzelewski, RA
Shurin, ZR
Rueger, RM
Trump, DL
Johnson, CS
Citation: Pa. Hershberger et al., 1,25-dihydroxycholecalciferol (1,25-D-3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo, CANCER RES, 59(11), 1999, pp. 2644-2649
Risultati:
1-12
|